Up 33% in 2019! A ‘perfect’ FTSE 100 growth stock I think I should buy for 2020

Royston Wild talks about a top FTSE 100 share that could soar again next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) has proved to be one of the FTSE 100’s big success stories of 2019. It has gained a whopping 33% in value since the turn of January, and the very same factors that have propelled it in the outgoing year look set to remain in place in 2020.

Demand for safe-haven stocks like pharmaceuticals manufacturers has been strong in 2019, the indispensable nature of their products providing the sort of earnings visibility that few others can match in turbulent times like these.

Issues like US-China trade wars, British politicians flirting with a so-called Hard Brexit, and worsening economic data from Asia and Europe have all boosted the likes of AstraZeneca recently, and these topics remain at the forefront of investors’ minds as we move into 2020.

Pound pressures

It’s worth mentioning the extra benefit that fears of a disorderly Brexit could have on AstraZeneca next year, such as a possible drop in the pound. The drugs giant does its reporting in US dollars and thus any sterling weakness provides profits with an additional tailwind.

Now the pound has been remarkably resilient in 2019 despite those continued tensions over the UK’s future relationship with the European Union. In fact, as I type, the British currency is up against those other major currencies, the euro and the greenback, surging from early October onwards as first a no-deal Brexit was taken off the table for mid-autumn, and then the Conservatives marched to victory at this month’s general election.

That said, it hasn’t exactly been a cakewalk for the pound in 2019. Let’s not forget that it slipped to multi-year lows against both the dollar and the single currency over the summer as fears of that no-deal Brexit reached fever pitch. And the chances of a Hard Brexit have risen markedly in recent days after Prime Minister Boris Johnson wrote into law that the UK will leave the European Union at the end of 2020, whether or not a trade deal is agreed upon.

Sales are soaring

It’s clear that the broader geopolitical and macroeconomic landscape should remain conducive for more share price gains for AstraZeneca in 2020. Though this is clearly only one half of the story, as recent data shows that 2019 has proved to be a blockbuster year for the company’s revenues column.

In Q3, sales of its new medicines jumped 62% to $2.7bn, underlining the impressive steps it has taken in recent years to rejuvenate its product pipeline. News today that it had received regulatory approval for new drugs in US and the China, for COPD and breast cancer respectively, accentuates the sense of strong momentum the Footsie firm has going into 2020.

City analysts expect earnings growth at AstraZeneca to accelerate to 19% in 2020 from 3% this year, illustrating the exceptional progress it’s making on the sales front. It might trade on a high forward P/E ratio of 24 times, but the strong chance of roaring profits growth well into the next decade makes the pharma ace worthy of such a premium, in my opinion. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Google office headquarters
Investing Articles

1 reason I like buying S&P 500 shares – and 1 reason I don’t

Will this investor try to improve his potential returns by focusing more on S&P 500 shares instead of British ones?…

Read more »

Young woman holding up three fingers
Investing Articles

3 SIPP mistakes to avoid

Our writer explains a trio of potentially costly errors he tries to avoid making when investing his SIPP, on an…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Here’s how (and why) I’d start buying shares with £25 a week

Our writer uses his investment experience and current approach to explain how he would start buying shares on a limited…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s my 5-step approach to earning passive income of £500 a month

Christopher Ruane explains the handful of steps he uses to target hundreds of pounds in passive income each month.

Read more »

Investing Articles

2 UK shares I’ve been buying this week

From a value perspective, UK shares look attractive. But two in particular have been attracting Stephen Wright’s attention over the…

Read more »

Investing Articles

A lifelong second income for just £10 a week? Here’s how!

With a simple, structured approach to buying blue-chip dividend shares at attractive prices, our writer's building a second income for…

Read more »

Investing Articles

Here’s how I’d use a £20k Stocks and Shares ISA to help build generational wealth

Discover how our writer would aim to turn a £20k Stocks and Shares ISA into a sizeable nest egg by…

Read more »

Investing Articles

Billionaire Warren Buffett just bought shares of Domino’s Pizza. Should I grab a slice?

Our writer takes a look at a few reasons why Domino's Pizza stock might have appealed to Warren Buffett's Berkshire…

Read more »